AI-generated research brief — verify at source
Inclisiran Cuts LDL by 28.5% in Adolescents With Familial Hypercholesterolaemia
In a phase 3 randomised trial, adolescents with heterozygous familial hypercholesterolaemia (HeFH) receiving inclisiran achieved a between-group LDL cholesterol reduction of 28.5 percentage points compared with placebo at day 330 (95% CI −35.8 to −21.3), with sustained reductions extending to two years. The magnitude of effect is clinically meaningful in a paediatric population where treatment options beyond statins remain limited.
What Was Studied
ORION-16 investigated whether inclisiran — a small interfering RNA (siRNA) that suppresses hepatic synthesis of PCSK9, a protein that degrades LDL receptors — could safely and effectively lower LDL cholesterol in adolescents with HeFH. Although inclisiran has demonstrated efficacy across multiple adult cohorts, no prior controlled data existed for paediatric patients with this inherited condition, which causes markedly elevated LDL from childhood and substantially increases long-term cardiovascular risk.
How It Was Studied
ORION-16 was a two-part, phase 3 randomised controlled trial conducted at 51 sites in 26 countries. Part 1 was a 12-month double-blind phase in which 141 adolescents aged 12 to under 18 years with HeFH and persistently elevated LDL cholesterol despite maximally tolerated statin therapy were randomised 2:1 to subcutaneous inclisiran sodium 300 mg or placebo, administered on days 1, 90, and 270. Part 2 was a 12-month open-label extension in which all participants received inclisiran. The primary endpoint was percentage change in LDL cholesterol from baseline to day 330. The study enrolled patients between February 2021 and December 2022, with a median participant age of 15.1 years; 53% were female and 91% were White.
What Was Observed
- Large, statistically robust LDL reduction in Part 1: Inclisiran produced a least squares mean LDL reduction of 27.1% from baseline by day 330, compared with a 1.4% increase in the placebo group — a between-group difference of 28.5 percentage points, a result highly unlikely to be due to chance (95% CI −35.8 to −21.3; p<0.0001). This is a substantial effect size for a twice-yearly subcutaneous injection regimen in adolescents already on background statin therapy.
- Durable efficacy through two years: In Part 2, the mean LDL reduction from original baseline reached 33.7% (SD 24.0) at day 720, suggesting that benefit is maintained and may deepen with continued dosing — an important consideration for a condition requiring lifelong management.
- Injection site reactions were more frequent with inclisiran but uniformly mild: In Part 1, 16% of inclisiran-treated patients experienced injection site reactions versus 6% of those receiving placebo. All reactions were mild in severity and none led to treatment discontinuation. The rate decreased to 9% in Part 2.
- No serious treatment-related adverse events or deaths: The overall safety profile was consistent with that observed in adult inclisiran trials, with no treatment-related serious adverse events reported in either part of the study, supporting tolerability in this younger age group.
Why This Matters
HeFH is among the most common inherited metabolic disorders, and the atherosclerotic burden begins accumulating in childhood, making early intervention a central research priority. Until now, evidence for PCSK9-targeting therapies in paediatric patients has been sparse, with this trial representing one of the first phase 3 evaluations of a siRNA lipid-lowering agent in adolescents. The twice-yearly dosing schedule distinguishes inclisiran from daily oral agents and from monthly injectable PCSK9 antibodies, which may have implications for adherence research in paediatric and adolescent populations.
How to Read This Result
The findings are encouraging but should be interpreted with caution given the relatively small sample size, the predominantly White study population limiting generalisability, the short two-year follow-up that precludes any conclusions about hard cardiovascular outcomes, and the open-label design of Part 2 which reduces the rigour of the long-term efficacy estimate.
Limitations
The abstract does not explicitly report study limitations. However, the trial enrolled a demographically narrow population (91% White) across a relatively small sample of 141 patients, which may constrain the applicability of findings to more diverse adolescent populations. The two-year timeframe is insufficient to assess effects on atherosclerosis progression or cardiovascular events, and Part 2’s open-label design introduces potential for performance bias in safety and tolerability assessments.